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Baseline body mass index among children and adults
undergoing allogeneic hematopoietic cell transplantation:
clinical characteristics and outcomes
M Gleimer1, Y Li2, L Chang3, S Paczesny4, DA Hanauer5,6, DG Frame7, CA Byersdorfer3, PR Reddy8, TM Braun2 and SW Choi3
Obesity is an important public health problem that may inﬂuence the outcomes of hematopoietic cell transplantation (HCT). We
studied 898 children and adults receiving ﬁrst-time allogeneic hematopoietic SCTs between 2004 and 2012. Pretransplant body
mass index (BMI) was classiﬁed as underweight, normal weight, overweight or obese using the WHO classiﬁcation or age-adjusted
BMI percentiles for children. The study population was predominantly Caucasian, and the median age was 51 years (5 months–73
years). The cumulative 3-year incidence of nonrelapse mortality (NRM) in underweight, normal weight, overweight and obese
patients was 20%, 19%, 20% and 33%, respectively. Major causes of NRM were acute and chronic GVHD. The corresponding
incidence of relapse was 30%, 41%, 37% and 30%, respectively. Three-year OS was 59%, 48%, 47% and 43%, respectively.
Multivariate analysis showed that obesity was associated with higher NRM (hazard ratio (HR) 1.43, P= 0.04) and lower relapse (HR
0.65, P= 0.002). Pretransplant plasma levels of ST2 and TNFR1 biomarkers were signiﬁcantly higher in obese compared with normal
weight patients (P= 0.04 and P= 0.05, respectively). The increase in NRM observed in obese patients was partially offset by a lower
incidence of relapse with no difference in OS.
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INTRODUCTION
Overweight or obesity is a complex, multifactorial chronic disease
that arises from social, behavioral, economic, cultural, physiologi-
cal and genetic factors.1 The prevalence of overweight and obesity
has increased substantially since the 1960s, resulting in a broad
range of health problems and economic consequences.2–5 An
estimated 1.4 billion adults (ages 20 and older) worldwide are
overweight or obese, with an additional 170 million overweight or
obese children and adolescents, one quarter of whom are under
the age of ﬁve.6,7 Evidence-based research has demonstrated the
relationship between obesity and high blood pressure, elevated
cholesterol, type 2 diabetes, stroke, congestive heart failure,
coronary heart disease, osteoarthritis, sleep apnea and respiratory
problems, as well as various cancers.2 As such, overweight and
obesity place individuals at very high risk for morbidity and
mortality.8
In the allogeneic hematopoietic cell transplantation (HCT)
setting, pretransplant comorbidities have shown prognostic
associations with acute GVHD and subsequent mortality.9 The
HCT comorbidity index (HCT-CI) is a tool that assigns a
pretransplant score for various organ dysfunctions, including
pulmonary, hepatic, cardiac and renal comorbidities.10,11 Obesity
is also included as one of the comorbidities and a score is assigned
based on BMI435 kg/m2 in adults or BMI for age of the 95th
percentile or higher in children. Although the role of obesity as an
independent risk factor on allogeneic transplant outcomes, such
as GVHD, relapse, nonrelapse mortality (NRM) and OS, has been
previously explored by several groups, inconsistencies have been
reported depending on the study population.12–24 Recently,
plasma biomarkers predictive of GVHD and NRM have been
identiﬁed.25–27 However, none of these studies examined bio-
markers according to BMI categories.
In the present study, we measured pretransplant BMI of pediatric
and adult patients undergoing allogeneic HCT. On the basis of the
greater risk for morbidity and mortality in overweight and obesity,
we hypothesized that allogeneic HCT recipients with increased
pretransplant BMI would have high risk of GVHD and NRM,
resulting in inferior OS, compared with normal weight patients. The
study design included a retrospective cohort analysis of allogeneic
HCT patients and their outcomes stratiﬁed by BMI at a single
institution over a 9-year study period. Plasma biomarkers were also
measured in patient samples prospectively and compared across
BMI categories relative to normal weight patients.
MATERIALS AND METHODS
Literature review
We used PubMed/MEDLINE and Google Scholar to identify previously
published peer-reviewed articles on the risk of BMI in outcomes after
allogeneic HCT. The search was restricted to studies published in the
English language between January 1994 and May 2014. We applied the
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following MeSH terms in the search: (‘obesity,’ OR ‘overweight’ OR ‘body
mass index’) AND (‘stem cell transplant’ OR ‘bone marrow transplant’). The
initial search yielded 23 manuscripts. Ten were excluded immediately,
because they contained either autologous9 or syngeneic1 transplants. Two
co-authors (MG and SWC) read the full text of the 13 remaining papers.
Supplementary Table S1 summarizes key outcomes from each of the
studies.
Deﬁnition of BMI
BMI was calculated as weight (kg) divided by height (m) squared.28 The
index was used either as a categorical variable to evaluate hazard ratios
(HRs) and 95% conﬁdence intervals (CIs). For adult patients (age⩾ 18
years), the categories were deﬁned according to the WHO:29 underweight
(BMIo18.5 kg/m2), normal weight (BMI 18.5–24.9 kg/m2), overweight (BMI
25.0–29.9 kg/m2) and obese (BMI⩾ 30.0 kg/m2). For children and adoles-
cents (ageso18 years), age-adjusted BMI were compared with the CDC
BMI for age group charts to obtain percentile rankings. Categories were
deﬁned as previously described:30 underweight (BMIo5th percentile),
normal weight (BMI 5th—84.9th percentile), overweight (BMI 85th—94.9th
percentile) and obese (BMI⩾ 95th percentile).
Study design
A retrospective cohort study was conducted of 988 consecutive allogeneic
HCT performed between 1 January 2004 and 31 December 2012. The study
was approved by the University of Michigan Institutional Review Board
(IRB). Only ﬁrst-time allogeneic HCT were included; 41 patients with prior
allogeneic transplants were therefore excluded. Fifty-six patients who
received umbilical cord blood transplants were excluded a priori to reduce
potential confounding. The total study population was 898 patients. Height
and weight information, documented within 2 weeks before the transplant
procedure (day 0), was retrieved from the University of Michigan’s
electronic health record (EHR). The BMI was computed for each individual,
as described above. Outcomes of the study included OS and the
cumulative incidences of acute and chronic GVHD, NRM and relapse.
Demographics and transplant characteristics
Demographics, including age at transplant, gender, race, ethnicity, disease
at transplant and number of prior autologous transplants were collected
for each patient and recorded in the integrated University of Michigan
Blood and Marrow Transplantation (BMT) Clinical Research Database and
Repository. Transplant data, including donor stem cell source, donor type
(related or unrelated), donor gender, HLA matching, CMV status of donor
and recipient at transplant, ABO and Rh blood types of donor and
recipient, conditioning regimen, CD34+ cell dose infused for transplant,
GVHD prophylaxis regimen, acute and chronic GVHD, time to engraftment
and comorbidity scores (low, intermediate or high) according to the HCT-
CI11 were also collected and recorded. Granulocyte colony-stimulating
factor was started on day 6 to promote neutrophil engraftment, which was
deﬁned as the ﬁrst of three consecutive days with ANC⩾ 500/mm3.
Electronic Medical Record Search Engine (EMERSE): chart review
Data abstraction of the above transplant variables was supported by the
use of the University of Michigan EMERSE, as previously described.31
A script was also devised to extract the latest available pretransplant
weight and height for the study population. These values were inspected
(MG and SWC) to ensure that they were measured within 14 days of the
transplant procedure.
Plasma biomarkers
Pretransplant blood samples were collected prospectively from allogeneic
HCT patients between January 2004 and May 2010, with informed
consents and in agreement with the Declaration of Helsinki. Samples were
collected in heparin-containing Vacutainer tubes (Becton Dickinson,
Franklin Lakes, NJ, USA) and underwent Ficoll (Amersham, Piscataway,
NJ, USA) gradient centrifugation to separate the plasma. Plasma
concentrations of suppression of tumorigenicity 2 (ST2), TNF receptor 1
(TNFR1) and IL 2 receptor alpha (IL2Rα) were measured in duplicate using
ELISAs according to the manufacturer’s protocol (R & D Systems,
Minneapolis, MN, USA), as previously described.25–27,32 Absorbances were
read using a SpectraMax M2e plate reader (Molecular Devices, Sunnyvale,
CA, USA). The integrated BMT Clinical Research Database and Repository
that contained demographic and transplant characteristics, as well as the
clinical outcomes (GVHD, NRM, relapse and survival), was linked to plasma
biomarker samples that were collected and stored in accordance with IRB-
approved protocols.
Statistical analysis
Demographics of all ﬁrst-time allogeneic HCT patients who received BM or
PBSC grafts were summarized. Counts and percentages were determined
for categorical variables. Medians and ranges were determined for
continuous variables. Cumulative incidences with competing risks were
determined using the methods of Fine and Gray33 and compared using the
test described by Gray.34 OS was compared using the Kaplan–Meier
method.35 Differences in characteristics between patient groups were
assessed with the Kruskal–Wallis test for continuous variables and the
χ2 test of association for categorical values. Differences in the distribution
of baseline plasma biomarker levels among categories of BMI were
assessed with the Kruskal–Wallis test. Multivariate analysis incorporating
possible confounders (age, malignant vs nonmalignant diagnosis, related
vs unrelated donor, HLA match vs mismatch, BM vs PBSC transplant, full vs
reduced intensity conditioning and transplant 2004− 2008 vs 2009− 2012)
while examining the association of BMI with acute and chronic GVHD,
NRM and relapse were assessed with competing risks regression33 and
with OS using Cox regression. Data were analyzed using R version
2.15.02 (GNU General Public License). Statistical signiﬁcance was deﬁned as
a P-value o0.05.
RESULTS
Patient and transplant characteristics of the study population
The median age of the study population was 51 years (range
5 months–73 years, interquartile range [IQR] 31–58 years),
comprised predominantly of adults (⩾18 years, 89%), males
(60%) and Caucasians (92%). Thirty-four percent of the population
was categorized as obese, 32% as overweight, 32% as normal
weight and 2% as underweight, with a median BMI of 26.9 kg/m2
(Table 1). The combined prevalence of pretransplant overweight
and obesity increased from 58% in 2004 to 69% in 2012, an
average increase of ~ 1.2% per year. The frequency of inter-
mediate or high comorbidity index (HCT-CI) was greatest in
overweight and obese patients (Table 1).
Ninety-four percent of patients had hematological malignan-
cies. Patients received HLA-matched related (47%), mismatched
related (3%), matched unrelated (38%) or mismatched unrelated
transplants (12%). HCT was performed using cells from peripheral
blood (PB, 85%) or BM (15%). Sixty-one percent of patients were
conditioned with myeloablative regimens (of these, 20% included
TBI⩾ 1200 cGy) and 39% with reduced intensity regimens,
according to the ASBMT working deﬁnitions.36 Six percent were
conditioned with regimens that involved antihuman T cell Ab
(ATG/thymoglobulin or alemtuzumab). CD34+ cells were infused at
a median concentration of 5.5 × 106 cells/kg (range 1.1 × 106–
1.75 × 107 cells/kg, IQR 4.6 × 106–6.9 × 106). Engraftment occurred
on median day 12 (range 5–28, IQR 11–13). Fifty-ﬁve percent of
transplants were performed between 2004 and 2008 and 45%
between 2009 and 2012 (detailed characteristics are presented in
Table 1).
NRM
The cumulative incidence of 3-year NRM in our population was
24%, and according to BMI categories (underweight, normal
weight, overweight and obese) was 20%, 19%, 20% and 33%,
respectively (Figure 1a). Across BMI categories, obese patients
were at greater risk of NRM at 3 years compared with normal
weight patients (HR 1.43, 95% CI 1.02–2.01, P= 0.04, Table 2).
Other variables signiﬁcantly associated with increased NRM in the
multivariate analysis were unrelated donor (Po0.001), PBSC as
transplant source (P= 0.002) and HLA mismatch (P= 0.004)
(Table 2). The major causes of NRM were acute GVHD (40%) and
chronic GVHD (45%) (Table 3).
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Table 1. Demographic and transplant characteristics of patients receiving HCT from 2004 to 2012 by BMI category
UW NW OW OB
Total (n= 898) 20 (2.2) 290 (32.3) 287 (32.0) 301 (33.5)
Age (years)
Pediatric (o18 years) 8 (0.9) 61 (6.8) 15 (1.7) 17 (1.9)
Adult 12 (1.3) 229 (25.5) 272 (30.3) 284 (31.6)
Gender
Male 10 (1.1) 132 (14.7) 197 (21.9) 201 (22.4)
Female 10 (1.1) 158 (17.6) 90 (10.0) 100 (11.1)
Race/ethnicity
White (non-Hispanic) 20 (2.2) 251 (28.0) 268 (29.8) 282 (31.4)
All other — 39 (4.3) 19 (2.1) 19 (2.1)
Disease
Malignant 16 (1.8) 257 (28.6) 279 (31.1) 293 (32.6)
Non-Hodgkin lymphoma 3 (0.3) 40 (4.5) 52 (5.8) 49 (5.5)
AML 6 (0.7) 89 (9.9) 108 (12.0) 114 (12.7)
ALL 2 (0.2) 40 (4.5) 31 (3.5) 45 (5.0)
Myelodysplastic syndrome — 17 (1.9) 33 (3.7) 29 (3.2)
Multiple myeloma 2 (0.2) 18 (2.0) 19 (2.1) 18 (2.0)
CLL 1 (0.1) 16 (1.8) 14 (1.6) 14 (1.6)
CML 1 (0.1) 11 (1.2) 6 (0.7) 6 (0.7)
Myeloﬁbrosis — 8 (0.9) 6 (0.7) 7 (0.8)
Myeloproliferative disorder 1 (0.1) 7 (0.8) 6 (0.7) 3 (0.3)
Hodgkin lymphoma — 8 (0.9) 2 (0.2) 6 (0.7)
Biphenotypic leukemia — 3 (0.3) 1 (0.1) 2 (0.2)
Histiocytic sarcoma — — 1 (0.1) —
Nonmalignant 4 (0.4) 33 (3.7) 8 (0.9) 8 (0.9)
SAA 2 (0.2) 14 (1.6) 4 (0.4) 4 (0.4)
Sickle cell disease — 8 (0.9) — —
Thalassemia 1 (0.1) 2 (0.2) 1 (0.1) —
Familial erythrophagocytic lymphohistiocytosis — 2 (0.2) — —
Paroxysmal nocturnal hemoglobinuria — 1 (0.1) 1 (0.1) —
SCID — 2 (0.2) — —
Severe congenital neutropenia — 1 (0.1) 1 (0.1) 1 (0.1)
X-linked lymphoproliferative syndrome — 1 (0.1) 1 (0.1) 1 (0.1)
IPEX — — — 1 (0.1)
Dyskeratosis congenita — 1 (0.1) — 1 (0.1)
Osteopetrosis 1 (0.1) — — —
Congenital dyserythropoietic anemia — 1 (0.1) — —
Transplant type/source
Overall
Peripheral blood (PB) 12 (1.3) 217 (24.2) 259 (28.8) 275 (30.6)
BM 8 (0.9) 73 (8.1) 28 (3.1) 26 (2.9)
HLA matching and relatedness
Matched related 11 (1.2) 148 (16.5) 130 (14.5) 129 (14.4)
Mismatched related — 8 (0.9) 10 (1.1) 11 (1.2)
Matched unrelated 7 (0.8) 102 (11.4) 107 (11.9) 128 (14.2)
Mismatched unrelated 2 (0.2) 32 (3.6) 40 (4.5) 33 (3.7)
Conditioning intensity
Myeloablative 9 (1.0) 182 (20.3) 176 (19.6) 184 (20.5)
TBI⩾ 1200 cGy
Yes 3 (0.3) 47 (5.2) 30 (3.3) 37 (4.1)
No 6 (0.7) 135 (15.0) 146 (16.3) 147 (16.4)
Reduced intensity 11 (1.2) 108 (12.0) 111 (12.4) 117 (13.0)
HCT-CI
Low 4 (57) 41 (35) 35 (28) 33 (23)
Intermediate 1 (14) 35 (30) 38 (30) 43 (29)
High 2 (29) 41 (35) 53 (42) 71 (48)
Conditioning Intensity
Myeloablative 9 (1.0) 182 (20.3) 176 (19.6) 184 (20.5)
TBI⩾ 1200 cGy
Yes 3 (0.3) 47 (5.2) 30 (3.3) 37 (4.1)
No 6 (0.7) 135 (15.0) 146 (16.3) 147 (16.4)
Reduced Intensity 11 (1.2) 108 (12.0) 111 (12.4) 117 (13.0)
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GVHD
The cumulative incidence of grade 2–4 acute GVHD in the study
population at day 100 was 37%. According to BMI categories
(underweight, normal weight, overweight and obese), the
incidences were 40%, 33%, 37% and 41%, respectively. In
adjusted models, categorical BMI (Table 2) was not signiﬁcantly
associated with acute GVHD. Variables signiﬁcantly associated
with acute GVHD in the multivariate analysis were unrelated
donor (Po0.001), PBSC as transplant source (P= 0.04), HLA
mismatch (Po0.001) and transplant before 2009 (P= 0.02)
(Table 2).
The cumulative incidence of chronic GVHD at 3 years was 46%,
which was greatest in obese patients (50%), followed by over-
weight, normal weight and underweight (46%, 42% and 40%,
respectively) (Figure 1b). After controlling for potential confoun-
ders, however, BMI as a categorical variable was not associated
with risk of chronic GVHD. There were no other variables that
signiﬁcantly predicted the risk of chronic GVHD (Table 2).
Table 1. (Continued )
UW NW OW OB
GVHD prophylaxis
Calcineurin inhibitor+MTX 10 (1.1) 203 (22.6) 162 (18.0) 188 (20.9)
Calcineurin inhibitor+mycophenolate mofetil 9 (1.0) 80 (8.9) 117 (13.0) 106 (11.8)
Calcineurin inhibitor alone 1 (0.1) 2 (0.2) 1 (0.1) —
Other — 5 (0.6) 7 (0.8) 7 (0.8)
Year of transplant
2004–2008 13 (1.4) 168 (18.7) 160 (17.8) 151 (16.8)
2009–2013 7 (0.8) 122 (13.6) 127 (14.1) 150 (16.7)
Abbreviations: BMI=body mass index; HCT=hematopoietic cell transplantation; HCT-CI=HCT comorbidity index; IPEX= immunodysregulation polyendocrino-
pathy enteropathy X-linked syndrome; NW=normal weight; OB=obese, OW=overweight; UW=underweight. HCT-CI Available for underweight (n= 7), normal
weight (n= 117), overweight (n= 126) and obese (n= 147). Data are shown as count (%) or median (range, interquartile range).
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Figure 1. Transplant outcomes by BMI category. Cumulative incidence of NRM, Po0.001*** (a), chronic GVHD, P= 0.07 (b), relapse, P= 0.02* (c)
and adjusted probability of OS, P= 0.13 (d). N= 20 underweight (UW), 290 normal weight (NW), 287 overweight (OW) and 301 obese (OB).
P-values represent outcomes of obese relative to normal weight patients.
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Relapse
The cumulative incidence of relapse in the study population at 3
years was 36%. On the basis of BMI groups (underweight, normal
weight, overweight and obese), the incidences were 30%, 41%,
37% and 30%, respectively (Figure 1c). In the adjusted models,
obese patients experienced signiﬁcantly decreased relapse when
compared with normal weight patients (HR 0.65, 95% CI 0.49–0.86,
P= 0.002, Table 2). Other variables associated with relapse in the
multivariate analysis included malignant disease (P= 0.002),
related donor (Po0.001) and transplant date before 2009
(P= 0.02) (Table 2).
OS
The 3-year OS of our study population was 46%, with the poorest
survival outcome of 43% in obese patients compared with 59%,
48% and 47% in the other BMI categories (underweight, normal
weight, and overweight, respectively) (Figure 1d). However, in
adjusted models, categorical BMI revealed no signiﬁcant associa-
tion with survival. Variables found to be associated with decreased
OS included patient age (P= 0.003), unrelated donor (P= 0.02),
PBSC as transplant source (P= 0.003), HLA mismatch (P= 0.03) and
transplant date before 2009 (P= 0.01) (Table 2).
Baseline levels of plasma biomarkers
Pretransplant plasma levels of proinﬂammatory biomarkers ST2,
TNFR1 and IL2Rα were measured by ELISA in a subset of patients.
The median ST2 concentration in obese patients (257 pg/mL, IQR
0–1045 pg/mL) was signiﬁcantly higher than in normal weight
patients (131 pg/mL, IQR 0–628, P= 0.04, Table 4). Likewise, the
median TNFR1 concentration was elevated in obese patients
(2644 pg/mL, IQR 1922–3395) compared with normal weight
patients (2129 pg/mL, IQR 1486–3232, P= 0.05, Table 5). The
concentration of IL2Rα was not signiﬁcantly different among BMI
categories (data not shown).
DISCUSSION
Obesity is a major public health problem worldwide.7,29,37 The
prevalence of obesity is rapidly rising, leading to serious social,
health and economic challenges.1,2,38 In this study, we set out to
Table 2. Clinical outcomes by BMI category
UW NW OW OB
Total 20 290 (34.5) 287 (32.0) 301 (33.5)
Follow-up time (months) 29.4 (0.8–113.7, 7.6–64.4) 18.9 (0.5–117.7, 5.7–50.0) 17.8 (0.3–117.6, 5.4–49.9) 17.8 (0.6–115.5, 5.9–43.4)
Hospital length of stay (days) 29 (18–68, 24–35) 24 (12–175, 21–29) 23 (0–154, 20–27) 23 (0–98, 21–26)
Acute GVHDa
Yes 9 (1.0) 159 (17.7) 174 (19.4) 178 (19.8)
1 — 42 (4.7) 50 (5.6) 36 (4.0)
2 4 (0.4) 69 (7.7) 64 (7.1) 76 (8.5)
3 4 (0.4) 24 (2.7) 25 (2.8) 32 (3.6)
4 1 (0.1) 24 (2.7) 35 (3.9) 34 (3.8)
No 11 (1.2) 131 (14.6) 113 (12.6) 123 (13.7)
Chronic GVHD
Yes 9 (1.0) 135 (15.0) 148 (16.5) 166 (18.5)
No 11 (1.2) 155 (17.3) 139 (15.5) 135 (15.0)
Relapse
Yes 6 (0.7) 116 (12.9) 107 (11.9) 91 (10.1)
No 14 (1.6) 174 (19.4) 180 (20.0) 210 (23.4)
Survival
Alive 10 (1.1) 133 (14.8) 122 (13.6) 116 (12.9)
Dead 10 (1.1) 157 (17.5) 165 (18.4) 185 (20.6)
Causes of death
Relapse 4 (40.0) 99 (63.1) 91 (55.2) 76 (41.1)
Acute GVHD 2 (20.0) 26 (16.6) 36 (21.8) 35 (18.9)
Chronic GVHD 2 (20.0) 20 (12.7) 27 (16.4) 57 (30.1)
Graft rejection or failure — 2 (1.3) 3 (1.8) 2 (1.1)
Idiopathic pneumonia syndrome — — 1 (0.6) 7 (3.8)
Infectionb 1 (10.0) 2 (1.3) 3 (1.8) 2 (1.1)
Hepatic veno-occlusive disorder — 1 (0.6) 1 (0.6) 3 (1.6)
Engraftment syndrome — — 1 (0.6) 1 (0.5)
Cardiac event — 1 (0.6) 1 (0.6) —
PTLD — 1 (0.6) — —
Pulmonary hypertension — 1 (0.6) — —
Small bowel obstruction — — — 1 (0.5)
Accidental trauma — — — 1 (0.5)
Otherc or unknown 1 (10.0) 4 (2.5) 1 (0.6) —
Abbreviations: BMI=body mass index; IQR= interquartile range; NW=normal weight; OB= obese; OW=overweight; PTLD=post-transplant lymphopro-
liferative disorder; UW=underweight. Data are shown as count (%) or median (range, IQR). aAcute GVHD onset day ⩽ 100 post transplant and not post relapse,
max grade shown. bAmong deaths from infection, one UW patient died from Pneumocystis jirovecii pneumonia, one NW patient from human herpes virus 6
meningoencephalitis, one NW, two OW and one OB patients from culture-negative sepsis, one OW patient from pneumonia of unknown etiology and one OB
patient from a bacterial infection at another hospital. cOne UW patient died from esophageal cancer; three NW patients died from lung cancer.
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Table 3. Results of multivariate regression analysis by BMI category
N HR (95% CI) P-value
aGVHD
BMI
Normal 290 1.00 —
UW 20 1.11 (0.56–2.21) 0.76
OW 287 1.03 (0.78–1.35) 0.85
OB 301 1.15 (0.89–1.50) 0.29
Other covariates — — —
Continuous age 898 1.00 (0.99–1.00) 0.37
Malignancy
Nonmalignant 53 1.00 —
Malignant 845 1.73 (0.82–3.68) 0.15
Relatedness
Related 447 1.00 —
Unrelated 451 1.88 (1.50–2.35) o0.001
Transplant type
PB 763 1.00 —
BM 135 0.66 (0.44–0.99) 0.04
HLA match
Matched 762 1.00 —
Mismatched 136 1.69 (1.30–2.17) o0.001
Conditioning intensity
Myeloablative 551 1.00 —
Reduced 347 1.19 (0.94–1.49) 0.14
Year of transplant
2004–2008 492 1.00 —
2008–2013 406 0.76 (0.61–0.95) 0.02
cGVHD
BMI
Normal 290 1.00 —
UW 20 0.99 (0.46–2.12) 0.98
OW 287 1.07 (0.83–1.38) 0.60
OB 301 1.21 (0.94–1.55) 0.14
Other covariates
Continuous age 898 1.00 (0.99–1.01) 0.69
Malignancy
Nonmalignant 53 1.00 —
Malignant 845 1.29 (0.72–2.31) 0.38
Relatedness
Related 447 1.00 —
Unrelated 451 1.13 (0.92–1.39) 0.23
Transplant type
PB 763 1.00 —
BM 135 0.91 (0.61–1.36) 0.65
HLA match
Matched 762 1.00 —
Mismatched 136 0.95 (0.73–1.25) 0.73
Conditioning intensity
Myeloablative 551 1.00 —
Reduced 347 1.02 (0.82––1.27) 0.82
Year of transplant
2004–2008 492 1.00 —
2008–2013 406 0.96 (0.79–1.17) 0.70
NRM
BMI
Normal 290 1.00 —
UW 20 1.74 (0.76–4.01) 0.19
OW 287 0.95 (0.65–1.37) 0.77
OB 301 1.43 (1.02–2.01) 0.04
Other covariates
Continuous age 898 1.01 (1.00–1.02) 0.18
Malignancy
Nonmalignant 53 1.00 —
Malignant 845 0.37 (0.10–1.33) 0.13
Relatedness
Related 447 1.00 —
Unrelated 451 2.20 (1.65–2.94) o0.001
Table 3. (Continued )
N HR (95% CI) P-value
Transplant type
PB 763 1.00 —
BM 135 0.23 (0.09–0.58) 0.002
HLA match
Matched 762 1.00 —
Mismatched 136 1.59 (1.16–2.22) 0.004
Conditioning intensity
Myeloablative 551 1.00 —
Reduced 347 1.02 (0.76–1.35) 0.91
Year of transplant
2004–2008 492 1.00 —
2008–2013 406 0.79 (0.60–1.05) 0.10
Relapse
BMI
Normal 290 1.00 —
UW 20 0.70 (0.32–1.50) 0.36
OW 287 0.79 (0.61–1.03) 0.08
OB 301 0.65 (0.49–0.86) 0.002
Other covariates
Continuous age 898 1.00 (1.00–1.01) 0.36
Malignancy
Nonmalignant 53 1.00 —
Malignant 845 26.50 (3.49– 201.02) 0.002
Relatedness
Related 447 1.00 —
Unrelated 451 0.61 (0.48–0.77) o0.001
Transplant type
PB 763 1.00 —
BM 135 1.09 (0.72–1.66) 0.68
HLA match
Matched 762 1.00 —
Mismatched 136 0.83 (0.60–1.18) 0.29
Conditioning intensity
Myeloablative 551 1.00 —
Reduced 347 0.90 (0.69–1.16) 0.42
Year of transplant
2004–2008 492 1.00 —
2008–2013 406 0.76 (0.60–0.95) 0.02
OS
BMI
Normal 290 1.00 —
UW 20 1.02 (0.54–1.95) 0.95
OW 287 0.85 (0.68–1.07) 0.17
OB 301 0.93 (0.75–1.16) 0.55
Other covariates
Continuous age 898 1.01 (1.00–1.02) 0.003
Malignancy
Non–malignant 53 1.00 —
Malignant 845 2.05 (0.92, 4.58) 0.08
Relatedness
Related 447 1.00 —
Unrelated 451 1.24 (1.03–1.49) 0.02
Transplant type
PB 763 1.00 —
BM 135 0.56 (0.38–0.82) 0.003
HLA match
Matched 762 1.00 —
Mismatched 136 1.41 (1.12–1.79) 0.003
Conditioning intensity
Myeloablative 551 1.00 —
Reduced 347 0.89 (0.74–1.09) 0.24
Year of transplant
2004–2008 492 1.00 —
2008–2013 406 0.78 (0.65–0.94) 0.01
Abbreviations: BMI=body mass index; CI= conﬁdence interval; HR=
hazard ratio; NRM=nonrelapse mortality; OB=obese; OW= overweight;
PB=peripheral blood; UW=underweight.
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investigate the impact of obesity on outcomes following
allogeneic HCT, including GVHD, NRM, relapse and OS. We found
that our population was comprised of 34% obese patients, which
was higher than expected based on the geographic locale of our
institution; in 2011, Michigan ranked 10th in USA among states
with the highest prevalence of obesity at 31.1% in adults age 20
years and older.39 The 34% of obese patients in our study was
striking, particularly because it was threefold higher compared
with the worldwide obesity estimate of 11%.7 This important
ﬁnding highlights the growing number of patients with con-
comitant obesity who are being treated for life-threatening
hematological malignancies and undergoing high-risk
allogeneic HCT.
Among allogeneic HCT recipients, the impact of obesity on
outcomes remains controversial.12–24 Here in, BMI examined either
as a categorical predictor did not signiﬁcantly change the overall
results and interpretations. After adjusting for other covariates, our
ﬁndings provided evidence that obese patients experienced
signiﬁcantly increased NRM and decreased relapse, with no
difference in OS compared with normal weight patients. Although
our study population was comprised predominantly of adults,
these observations are concordant with a recent registry-based
analysis of 3687 pediatric patients (age 2–18 years).12
Obesity in solid organ transplantation has been shown to be
associated with worse outcomes, including delayed graft function,
graft failure, surgical site infection, cardiovascular disease,
prolonged hospital course and increased healthcare costs.40
Interestingly, our data show that obesity was associated with
signiﬁcantly decreased risk of relapse, in agreement with two large
registry data studies.12,20 By contrast, a single-center study of 325
children reported a higher incidence of relapse in obese
patients,14 highlighting the challenges of comparing results across
studies with heterogeneous populations. It is important to
consider that BMI does not distinguish excess body fat from lean
mass.41 In addition, the pharmacokinetics and distribution of
drugs in different tissues may vary across the range of BMI and
thereby impact outcomes.42 Alternatively, decreased relapse may
not have been a direct result of excessive fat stores or obesity. For
instance, the mechanisms underlying the increased frequency of
chronic GVHD in obese patients may have offered protection
against relapsed disease (GVL effect).43 It is also possible that our
institutional practice of chemotherapy dose modiﬁcations
according to adjusted ideal body weight compared with actual
weight may have impacted the risk of NRM and relapse. The
potential effects of these adjustments on outcomes are not well
understood. Further investigation is warranted to conﬁrm the
ﬁndings reported herein.
Obesity is strongly associated with metabolic abnormalities and
likely to be mediated in part by a chronic inﬂammatory state
induced by secretion of cytokines in the adipocytes, such as TGF-
β, TNF-α, IL-6 and angiotensinogen.44 We have previously shown
that ST2, TNFR1 and IL2Rα can predict GVHD and NRM after
allogeneic HCT.25–27 We were therefore interested to know
whether these biomarkers differed across a range of BMI. We
found that obese patients had higher plasma levels of ST2 and
TNFR1 at the time of transplant. ST2, a decoy receptor for IL-33
secreted by epithelial cells, endothelial cells and ﬁbroblasts in
response to proinﬂammatory stimuli, biases T cells toward a TH1
phenotype and its high levels are associated with acute GVHD,
resistance to GVHD treatment and NRM.27 TNFR1, a receptor and
surrogate marker for TNFα, which is shed from the cell surface
following ligand binding, is a signiﬁcant predictor of GVHD and
NRM.25 Elevated ST2 levels have previously been reported in
serum and adipose tissue of obese humans,45 adipose tissue of
diet-induced obese mice45 and in the serum of rats fed a high-fat
diet.46 TNFR1 is also present at an increased level in obese
individuals47 and can be lowered with exercise and weight loss.48
Our recapitulation of these ﬁndings in an HCT cohort may provide
a basis for future studies of the molecular mechanisms linking
obesity with transplant outcomes.
To our knowledge, this is the ﬁrst study in HCT to measure
baseline biomarkers and correlate them across BMI categories.
Clearly, further investigation of these biomarkers is needed.
Target-speciﬁc biomarkers that can help inform about risks and
outcomes in the HCT setting may assist in risk stratiﬁcation for risk-
adapted clinical trials. For instance, depending on the patient’s
pre-HCT disease characteristics, BMI, HCT-CI and/or biomarkers
levels, the transplant team may begin to stratify patients
according to low risk vs high risk. The pathogenesis of GVHD
involves a complex network of proinﬂammatory cytokines.25
Therefore, in the present study, it was not surprising that in
obese individuals higher baseline levels of TNFR1 and ST2 were
associated with increased risk of developing GVHD. Thus, future
discovery of biomarkers in the early pre-HCT setting is warranted
to better develop risk-adapted treatment strategies. Importantly,
they may provide insight into the delicate balance between
relapse and GVHD and NRM.
The current study was conducted over nearly a decade in 898
children and adults undergoing ﬁrst-time allogeneic HCT,
predominantly due to hematological malignancies. Strengths of
the study included a large, heterogeneous population with an
array of sociodemographic data, including patient age, underlying
disease, stem cell source and conditioning regimen and the
prospective evaluation of plasma biomarkers before transplant,
allowing us to form generalized conclusions. At the same time, we
recognize this heterogeneous patient population is also a
limitation, precluding us from detecting associations that may
have reached signiﬁcance if potential confounders, such as age
(pediatric vs adult) or type of transplant (full vs reduced intensity
conditioning), were restricted. Nonetheless, we attempted to
control for this by performing multivariate analyses with other
covariates and with BMI modeled as both a categorical and
continuous (data not shown) variable. Our results were largely
unchanged by both these approaches. Furthermore, we per-
formed a subgroup analysis of children o18 years of age and
patients with ALL, AML and myelodysplastic syndrome. Although
the sample sizes were very small, we found no differences in
outcomes (GVHD, NRM, relapse and survival) between the overall
study population and these subgroups (Supplementary Table S2).
Clearly, future studies are needed with larger populations to
Table 4. Baseline levels of plasma biomarker ST2 by BMI category
BMI category N Median concentration (IQR), pg/mL P-value
Normal 115 131 (0–628) —
UW 7 256 (82–659) 0.51
OW 115 208 (0–845) 0.22
OB 110 257 (0–1045) 0.04
Abbreviations: BMI=body mass index; IQR= interquartile range; OB=
obese; OW=overweight.
Table 5. Baseline levels of plasma biomarker TNFR1 by BMI category
BMI category N Median concentration (IQR), pg/mL P-value
Normal 88 2129 (1486–3232) —
UW 7 1596 (1467–2971) 0.57
OW 81 2266 (1708–3725) 0.32
OB 99 2644 (1922–3395) 0.05
Abbreviations: BMI=body mass index; IQR= interquartile range; OB=
obese; OW=overweight; UW= underweight.
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address these effects along with considerations of race and
ethnicity. Our patient population was primarily Caucasian with
very few Asians, Hispanics and Blacks, and we recognize that
ﬁndings may differ across these populations. In addition, other
confounding factors, such as smoking and alcohol use, that may
impact the association of body weight with mortality were not
included in our analyses.
In conclusion, the current results showed increased NRM but
decreased relapse in obese patients undergoing allogeneic HCT.
To our knowledge, this study is the ﬁrst to report signiﬁcantly
elevated pretransplant levels of ST2 and TNFR1 among obese
patients relative to normal weight patients. Our data argue for a
well-designed prospective study that incorporates correlative
laboratory analyses,25–27 which may improve our understanding
of the impact of BMI on transplant outcomes.11 Although obesity
is an important risk factor for development of other comorbid
complications, such as hypertension, dyslipidemia, cardiovascular
diseases and diabetes mellitus, we recognize that the presence of
these disturbances may vary widely among obese individuals.
Nonetheless, obesity-related comorbidities should be routinely
assessed and treated by appropriate specialists working closely
with the transplant team. Accordingly, explaining these risks could
inform post-HCT expectations.
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